News
EC approves BMS’ Opdivo as adjuvant treatment for oesophageal or GEJ cancer patients
Bristol Myers Squibb (BMS) has announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with oesophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).